AbClon Inc. #1401 285, Digital-ro, Guro-gu, Seoul, Republic of Korea
Even at this moment AbClon is making history as a global biopharmaceutical company
KDDF fund granted for AT101 clinical study.
AT101 First patient in (Asan Medical center).
AT101 clinical study (Phase 1/2) IND approval in Korea.
AC101 (HLX22 at Shanghai Henlius Biotech) entered into Phase 2 in China.
Establishment of GMP facility for CAR-T treatment (AbClon Seoul HQ).
AC101 (HLX22 at Shanghai Henlius Biotech) entered into Phase 1 in China.
Listed on the KOSDAQ market.
AC101 out-licensed to Shanghai Henlius Biotech.
AbClon Inc. established (Seoul, Korea).